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Plasma Leptin and Prognosis in Patients
ith Established Coronary Atherosclerosis
obert Wolk, MD, PHD,*† Peter Berger, MD, FACC,* Ryan J. Lennon, MS,‡
mmanouil S. Brilakis, MD,* Bruce D. Johnson, PHD,* Virend K. Somers, MD, PHD, FACC*†
ochester, Minnesota
OBJECTIVES This study was designed to evaluate the relationship between plasma leptin and prognosis in
patients with angiographically confirmed coronary atherosclerosis.
BACKGROUND Experimental studies suggest that leptin, an adipose tissue-derived hormone, exerts important
cardiovascular effects.
METHODS Study subjects were recruited prospectively from a cohort of patients undergoing clinically
indicated coronary angiography (n  382). The median duration of follow-up was four years.
Follow-up information was available for 361 patients.
RESULTS The combined end point of cardiac death, myocardial infarction (MI), cerebrovascular
accident, or re-vascularization occurred in 44 subjects. In the simple Cox model, leptin had
a significant (p  0.001) non-linear/cubic univariate relationship with the combined end
point. Other variables associated with prognosis in the univariate analysis were body mass
index (BMI), prior MI, insulin resistance, C-reactive protein (CRP), fibrinogen, and number
of coronary vessels with 50% stenosis. A positive relationship between leptin and prognosis
was also seen when leptin levels were split by quintiles, with a hazard ratio of 6.46 for the
highest quintile. The only two variables significantly associated with the combined end point
in the multivariate Cox model were leptin (p  0.004) and number of coronary vessels with
50% stenosis (p 0.001). A similar relationship between leptin and prognosis was observed
when leptin was adjusted for BMI.
CONCLUSIONS In patients with angiographically confirmed coronary atherosclerosis, leptin is a novel
predictor of future cardiovascular events independent of other risk factors, including lipid
status and CRP. (J Am Coll Cardiol 2004;44:1819–24) © 2004 by the American College
ublished by Elsevier Inc. doi:10.1016/j.jacc.2004.07.050of Cardiology Foundation
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fhe adipose tissue-related hormone leptin (1) has been
ncreasingly implicated in increased cardiovascular risk.
lthough originally viewed as a mediator involved mainly in
nergy homeostasis, several cardiovascular actions of leptin
such as sympathetic activation, pressor effects, regulation of
ascular function, insulin resistance, enhancement of plate-
et aggregation, and proangiogenic effects) (2–12) suggest
hat leptin may also play an important role in the develop-
ent of cardiovascular disease. Consistent with this notion
re the results of two nested case-referent studies indicating
hat leptin might be a risk factor for myocardial infarction
MI) and stroke (13,14).
In a large prospective study of leptin and cardiovascular
isk, which utilized the West of Scotland Coronary Preven-
ion Study (WOSCOPS) population, leptin was found to be
modest but independent predictor of coronary events
uring a five-year follow-up period (15). However, a smaller
tudy on the Quebec Cardiovascular Study population
ound no association between leptin levels and coronary
vents (16). Both studies included only male subjects.
urthermore, relatively low-risk populations were investi-
ated in both studies. In the Quebec study, only subjects
ree of ischemic heart disease were included. The
From the Divisions of *Cardiovascular Diseases, †Hypertension, and ‡Biostatistics,
ayo Clinic, Rochester, Minnesota. This study was supported by Mayo Foundation
rants HL-61560, HL-65176, HL-70302, and MO1-RR00585.m
Manuscript received June 7, 2004; revised manuscript received July 23, 2004,
ccepted July 28, 2004.OSCOPS population consisted of moderately hypercho-
esterolemic men who had not had an MI and did not
xhibit any other major manifestations of coronary artery
isease. The pathophysiologic role and predictive value of
eptin may be different in patients with established coronary
therosclerosis, with possible implications for secondary
revention and risk stratification.
We evaluated the prognostic value of plasma leptin levels
n a large cohort of higher-risk patients with angiographi-
ally confirmed coronary atherosclerosis.
ETHODS
he study was approved by the Mayo Clinic Institutional
eview Board. All subjects with clinical indications for
ngiography were recruited prospectively in a cardiac
atheterization laboratory at the Mayo Clinic, Rochester,
innesota, between June and December 1998. The most
ommon indications for angiography included chest pain,
n abnormal imaging study, or dyspnea on exertion. Exclu-
ion criteria included diabetes, smoking history 50 pack-
ears, history of organ transplantation, prior coronary re-
ascularization, bleeding disorders, blood transfusion within
0 days, human immunodeficiency virus infection, renal
ailure, prior chest radiation therapy, and pregnancy.
Blood samples were drawn at baseline after an overnight
ast. Insulin resistance was calculated using the homeostasis
odel assessment (HOMA) (17). Leptin was measured by
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Leptin and Prognosis in CAD November 2, 2004:1819–24he Human Leptin double-antibody radioimmunoassay kit
Linco Research Inc., St. Louis, Missouri) and high-
ensitivity C-reactive protein (CRP) was measured on the
itachi 912 chemistry analyzer (Roche Diagnostics Corp.,
ndianapolis, Indiana) by a polystyrene particle enhanced
mmunoturbidimetric assay from DiaSorin (Stillwater,
innesota).
Of the original consecutively recruited 504 subjects, we
ncluded in this analysis patients with one or more coronary
rtery stenoses on angiography of 10% (n  382). Of
hese subjects, 41% had an unstable coronary syndrome on
dmission and the remaining 59% had stable coronary artery
isease. The angiograms were assessed by one or two
bservers (blind to leptin levels or other risk factors) by
isual estimate or hand-held calipers. In addition to calcu-
ating the number of coronary vessels with 50% stenosis,
he angiograms were also analyzed according to the segmen-
al classification proposed in the Coronary Artery Surgery
tudy (CAGE coronary extent scores) (18). Although the
AGE scores correlated well with the number of coronary
essels with 50% stenosis (Pearson correlation coefficient
0.81, p  0.0001), we found that they did not improve
he model’s ability to predict events. The model using the
umber of diseased vessels actually appeared to be better
the global likelihood ratio test statistic for the model with
he CAGE scores was 44.9 [14 df], whereas for the model
ith number of diseased vessels it was 56.9 [14 df]).
herefore the CAGE scores were not used in the final
nalysis.
All 382 subjects were followed up for the presence of any
f the following events: cardiac death, new MI, cerebrovas-
ular accident (CVA), and revascularization (percutaneous
oronary intervention [PCI] or coronary artery bypass graft-
ng [CABG]). Readmission for restenosis followed by
e-vascularization was considered an end point. Within the
rst month after the index angiography, 107 patients were
e-vascularized by CABG and 99 were re-vascularized by
CI. These procedures were not “new events” and did not
ount as adverse events occurring during follow-up because
hey were dictated by the results of the index angiography.
tatistical analysis. Continuous variables with little to
ild skewness were summarized as mean values  SD and
ontinuous variables with skewed distributions were sum-
arized as median values (first, third quartile). Discrete
Abbreviations and Acronyms
BMI  body mass index
CABG  coronary artery bypass grafting
CRP  C-reactive protein
CVA  cerebrovascular accident
HDL  high-density lipoprotein
LDL  low-density lipoprotein
MI  myocardial infarction
PCI  percutaneous coronary interventionariables are summarized as frequencies and percentages. phe association between leptin and continuous variables
as assessed using Spearman’s correlation coefficient; for
iscrete variables a rank-sum test was employed.
Hazard ratios were calculated using simple (univariate)
nd multiple (multivariate) Cox models. The combined end
oint of cardiac death, MI, CVA, or re-vascularization was
sed. If a subject had several different events, only the first
vent and the time to this first event were considered in the
nalysis. Noncardiac mortality was treated as a right-
ensored event time (n  8). The following variables were
elected for covariance adjustment, based on clinical signif-
cance: age, gender, smoking status, prior MI, unstable
ngina or acute MI on admission, mean blood pressure,
RP, low-density lipoprotein (LDL) to high-density li-
oprotein (HDL) ratio, insulin resistance, fibrinogen, and
umber of coronary vessels with significant stenoses (50%
eduction in luminal diameter). Because of skewness, log
ransformations of CRP, leptin, leptin to body mass index
BMI) ratio, insulin resistance, and LDL/HDL ratio were
sed. A cubic polynomial function of leptin was used due to
he evidence of a nonlinear/cubic relationship between
eptin and follow-up events. A likelihood ratio test with
hree degrees of freedom was used to test the hypothesis of
o overall leptin association with events.
Missing values for leptin (n  2), CRP (n  2), insulin
n 1), glucose (n 1), and the LDL/HDL ratio (n 10)
ere replaced with sample medians.
All continuous variables were standardized to have zero
ean and an SD of 1 in the models so that the presented
azard ratio is for a 1-SD change in the variable. Skewed
ariables were standardized after the logarithmic transfor-
ation. The quadratic and cubic leptin terms represent
quared and cubed values of the standardized log-leptin
ariable. All hypothesis tests were two-tailed with a 0.05
ype I error rate. SAS version 8.2 (Cary, North Carolina)
oftware was used for data analysis. PROC PHREG was
sed to analyze long-term survival, PROC CORR was used
o estimate correlations, and PROC NPAR1WAY was
sed to calculate rank sum tests. PROC STDIZE was used
o standardize continuous variables.
ESULTS
f the original 382 subjects, follow-up information was
vailable in 361 patients (95%). Baseline demographic and
linical characteristics of this cohort are shown in Table 1.
Leptin values were skewed to the right with a median of
.2 ng/ml and a range of 0.7 to 90.6 ng/ml. Leptin was
ositively correlated with female gender (p  0.001); BMI
p  0.001); HDL cholesterol; HDL/LDL ratio and
riglycerides (p  0.002, p  0.004, and p  0.001,
espectively); glucose, insulin, and insulin resistance (p 
.002, p  0.001, and p  0.001, respectively); CRP (p 
.001); fibrinogen (p  0.001); hypertension (p  0.001);
ean blood pressure (p  0.003); and systolic bloodressure (p  0.001). There was no difference in baseline
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November 2, 2004:1819–24 Leptin and Prognosis in CADlasma levels of leptin between the patients originally
dmitted with an unstable coronary syndrome and those
ith stable coronary artery disease (median [Q1, Q3]: 8.3
5.3, 17.1] ng/ml vs. 9.9 [5.6, 19.1] ng/ml, respectively; p
.53).
The patients were followed up for a median of four years
the 25th and 75th percentiles were 3.9 and 4.2 years,
espectively). During the follow-up, the combined end point
f cardiac death, MI, CVA, or re-vascularization was seen
n a total of 44 subjects (5 cardiac deaths, 12 MIs, 12 PCIs,
CABGs, 6 CVAs). The adverse follow-up events were
venly distributed between patients originally admitted with
n unstable coronary syndrome (20 events) and those with
table coronary artery disease (24 events).
In the simple Cox model, leptin had a significant (p 
.001) nonlinear/cubic univariate relationship with the
ombined end point (Fig. 1, Table 2). Other variables
ssociated with prognosis in the univariate analysis were
MI, prior MI, insulin resistance, CRP, fibrinogen, and
umber of coronary vessels with 50% stenosis (Table 2).
hen leptin was analyzed as a categorical variable split by
uintiles, a similar positive relationship was seen between
eptin and worse prognosis, with a hazard ratio of 6.46 (95%
able 1. Baseline Demographic and Clinical Characteristics
ge (yrs) 62  10
ale, n (%) 252 (70%)
MI 29.4  4.9
nstable angina/acute MI on admission, n (%) 148 (41%)
rior MI, n (%) 73 (20%)
urrent smoker, n (%) 28 (8%)
ypertension, n (%) 187 (52%)
ystolic blood pressure (mm Hg) 133  25
iastolic blood pressure (mm Hg) 72 12
ean blood pressure (mm Hg) 97  15
eptin (ng/ml), median (Q1, Q3) 9.2 (5.4, 17.5)
Log(leptin) 2.27 0.82
eptin/BMI, median (Q1, Q3) 0.32 (0.20, 0.58)
Log(leptin/BMI) 1.10  0.75
yperlipidemia, n (%) 227 (63%)
otal cholesterol (mg/dl) 209 46
DL cholesterol (mg/dl) 46 12
DL cholesterol (mg/dl) 127 37
DL/HDL ratio, median (Q1, Q3) 2.78 (2.13, 3.70)
Log(LDL/HDL ratio) 1.01 0.39
riglycerides (mg/dl) 180  104
lucose (mg/dl) 91 14
nsulin (U/ml) 6.1  4.1
nsulin resistance, median (Q1, Q3) 1.12 (0.74, 1.71)
Log(insulin resistance) 0.13  0.68
igh-sensitivity CRP (mg/l), median (Q1, Q3) 2.9 (1.2, 6.7)
Log(CRP) 1.12 1.33
ibrinogen (mg/dl) 467  127
oronary vessels with 50% stenosis, n (%)
0 99 (27%)
1 83 (23%)
2 77 (21%)
3 102 (28%)
MI  body mass index; CRP  C-reactive protein; HDL  high-density
ipoprotein; LDL  low-density lipoprotein; MI  myocardial infarction.onfidence intervals 1.45 to 28.7) for the highest quintile of feptin (Fig. 2). Figure 3 shows the Kaplan-Meier estimated
urvival curves for the leptin quintile groups.
The only two variables significantly associated with the
ombined end point in the multiple Cox model were leptin
p  0.004) and number of coronary vessels with 50%
tenosis (p  0.001) (Table 3). The relationship between
eptin levels and hazard ratios in Cox regression analyses is
hown in Figure 1.
When leptin was corrected for BMI and expressed as
eptin/BMI ratio, a similar cubic relationship was observed
etween BMI-corrected leptin and the combined end point,
oth in univariate (p  0.001) and multivariate (p  0.003)
nalyses (Tables 2 and 3).
In a separate model we also considered only the “hard”
nd points (cardiac death, MI, and CVA). Also in this case,
e found significant multivariate associations between car-
iovascular events and leptin (p  0.026) as well as
eptin/BMI ratio (p  0.007). These hard end points were
lso significantly linked to number of coronary vessels with
50% stenosis (multivariate analysis: p  0.053 with
ncorrected leptin in the model, and p  0.032 with
eptin/BMI ratio in the model).
Because 41 out of 44 follow-up events occurred in
atients with 50% coronary artery stenosis (262 subjects),
e also performed a subanalysis in this subgroup. Similar to
he results in the entire study group, the only two indepen-
ent multivariate predictors of prognosis in this subgroup
ere leptin (p  0.01) and the number of diseased vessels
p  0.001).
In contrast to its effects on cardiovascular events, leptin
as not a significant predictor of all-cause mortality.
ISCUSSION
he novel finding of this prospective study was that plasma
eptin level is an independent predictor of cardiovascular
vents among patients with coronary atherosclerosis con-
rmed by angiography. Using a multivariate Cox model, the
nly variables positively correlated with the combined end
oint were leptin (both uncorrected and corrected for BMI)
nd number of coronary vessels with significant stenoses.
The pathophysiologic mechanisms underlying the predic-
ive value of leptin cannot be directly inferred from the
resent study and are probably multifactorial (2–12). How-
ver, in the present study the adverse prognostic effects of
eptin were independent of inflammation (CRP), insulin
esistance, dyslipidemia, fibrinogen, and blood pressure, as
ell as the angiographic severity of coronary artery disease.
he negative prognostic association of hyperleptinemia is
hus likely due to other factors such as increased sympa-
hetic activity, enhanced platelet aggregation, increased
xidative stress, or paraoxonase-reducing effects (2,3,
0,19,20). Possible explanations may also relate to the
ssociation of leptin with left ventricular hypertrophy (21–
3), although the actual nature of this association requires
urther studies (24,25).
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Leptin and Prognosis in CAD November 2, 2004:1819–24The balance between the potentially detrimental
2,3,8,9–12,22,23) and beneficial (4–7,26) actions of leptin
ay help explain our observation of a nonlinear relationship
etween leptin and prognosis (Fig. 1). We speculate that
igure 1. The cubic relationship between leptin levels and hazard ratios fo
eptin is plotted on a logarithmic scale.
able 2. Univariate Hazard Ratios for the Combined End Point
Cardiac Death, MI, CVA, or Revascularization)
Hazard Ratio (CI) p Value
ge 1.20 (0.87–1.64) NS
ale 0.94 (0.50–1.77) NS
MI 1.28 (1.00–1.63) 0.046
nstable angina/acute MI on
admission
1.18 (0.65–2.14) NS
rior MI 2.33 (1.25–4.32) 0.007
urrent smoker 0.26 (0.04–1.90) NS
ypertension 1.24 (0.68–2.25) NS
ean blood pressure 1.02 (0.76–1.38) NS
eptin 0.001
Log(leptin) 0.62 (0.29–1.29) NS
Log(leptin)2 1.02 (0.61–1.69) NS
Log(leptin)3 2.19 (1.35–3.54) 0.001
eptin/BMI 0.001
Log(leptin/BMI) 0.54 (0.22–1.28) NS
Log(leptin/BMI)2 1.22 (0.68–2.19) NS
Log(leptin/BMI)3 3.01 (1.48–6.12) 0.002
og(LDL/HDL) 1.20 (0.88–1.64) NS
og(insulin resistance) 1.69 (1.27–2.24) 0.001
og(CRP) 1.39 (1.05–1.84) 0.021
ibrinogen 1.39 (1.10–1.75) 0.007
oronary vessels with 50% stenosis 2.11 (1.54–2.90) 0.001a
c
I  confidence interval; CVA  cerebrovascular accident; NS  not significant;
ther abbreviations as in Table 1.ardiovascular risk increases between the lowest leptin levels
nd the “plateau phase” owing to the detrimental effects of
eptin. The risk then plateaus, perhaps because of the
nfluence of some beneficial effects of leptin. With even
reater levels of leptin, the risk increases further. Part of this
combined end point. The leptin value of 4 ng/ml was taken as reference.
igure 2. Association between leptin (determined by the sample quintiles)
nd hazard ratios for the combined end point. The bars indicate 95%
onfidence intervals. The reference level is the first quintile.
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November 2, 2004:1819–24 Leptin and Prognosis in CADmbalance may be related to the phenomenon of selective
eptin resistance (27). Although this seems to be a plausible
xplanation, further studies are needed to clarify this ques-
ion. It is important, however, that even in the plateau phase
he risk is still greater than that for patients with the lower
eptin values.
The finding of leptin as a prognostic factor in patients
ith coronary atherosclerosis may conceivably have impor-
ant implications for novel cardiovascular therapies. Specif-
cally, identification of those mechanisms underlying the
eleterious effects of leptin on the cardiovascular system may
rovide a basis for new therapeutic and preventive interven-
ions. In support of this proposition is the observation that
fish-rich diet (which has well-established beneficial car-
iovascular effects) is associated with lower plasma leptin
evels (28).
tudy limitations. Some limitations of the present study
hould be acknowledged. First, our patient sample consisted
igure 3. Kaplan-Meier survival free of cardiac death, myocardial infarctio
ote the truncated ordinate axis.
Table 3. Multivariate Hazard Ratios for the C
Leptin Values or Leptin Values Corrected for
Unco
Hazard Ra
Age 0.92 (0.65
Male 1.17 (0.46
Unstable angina/MI on admission 0.55 (0.26
Prior MI 1.32 (0.63
Current smoker 0.47 (0.06
Mean blood pressure 1.11 (0.79
Leptin
Log(leptin) 0.67 (0.25
Log(leptin)2 1.22 (0.73
Log(leptin)3 2.05 (1.24
Log(LDL/HDL) 0.94 (0.67
Log(insulin resistance) 1.24 (0.85
Log(CRP) 1.22 (0.82
Fibrinogen 1.12 (0.78
Coronary vessels with 50% stenosis 2.20 (1.55Abbreviations as in Tables 1 and 2.f subjects referred for coronary angiography with evidence
f some coronary artery disease. We further excluded
atients with other coexisting conditions associated with
ncreased cardiovascular risk in their own right (including
iabetes, significant smoking history, prior revascularization,
rior radiation to the chest, and renal failure). These strict
xclusion criteria decrease the complexity of the pathophysi-
logic processes involved and are therefore important to
nderstand better any mechanistic interpretation of our
ata. Nevertheless, extrapolation of any conclusions from
his study to other populations may be incorrect and future
tudies in other clinical cohorts are warranted. Second, this
s an observational follow-up study, so no inferences can be
ade as to whether the modulation of leptin levels could
ffect cardiovascular risk. Finally, follow-up was unavailable
n 5% of subjects, and it is possible that some events were
ot captured.
ebrovascular accident, and revascularization for the leptin quintile groups.
ned End Point Using Uncorrected (Absolute)
(i.e., Leptin/BMI ratio)
d Leptin BMI-Corrected Leptin
I) p Value Hazard Ratio (CI) p Value
) NS 0.90 (0.63–1.28) NS
) NS 1.05 (0.39–2.78) NS
) NS 0.53 (0.25–1.11) NS
) NS 1.35 (0.64–2.86) NS
) NS 0.45 (0.06–3.54) NS
) NS 1.07 (0.76–1.50) NS
0.004 0.003
) NS 0.60 (0.19–1.91) NS
) NS 1.51 (0.83–2.73) NS
) 0.005 2.74 (1.30–5.77) 0.008
) NS 1.05 (0.77–1.45) NS
) NS 1.28 (0.88–1.87) NS
) NS 1.23 (0.83–1.81) NS
) NS 1.09 (0.76–1.57) NS
) 0.001 2.21 (1.56–3.14) 0.001ombi
BMI
rrecte
tio (C
–1.30
–2.98
–1.15
–2.75
–3.67
–1.57
–1.75
–2.04
–3.40
–1.33
–1.80
–1.81
–1.61
–3.13
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Leptin and Prognosis in CAD November 2, 2004:1819–24onclusions. In patients with established and angio-
raphically confirmed coronary atherosclerosis, plasma lep-
in level is a novel predictor of future cardiovascular events.
his association is independent of other traditional meta-
olic and cardiovascular risk factors, including lipid status
nd CRP. These findings may have important implications
oth for clinical risk stratification and for understanding the
athophysiologic mechanisms underlying cardiovascular
orbidity and mortality.
eprint requests and correspondence: Dr. Virend K. Somers,
ayo Clinic, Saint Mary’s Hospital, 1216 Second Street SW,
ochester, Minnesota 55902. E-mail: somers.virend@mayo.edu.
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